BioMarin Pharma (BMRN) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $57.29 -2.09%
Financial Fact:
Selling, general and administrative: 118.76M
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Selling, general and administrative: 118.76M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.20), $0.04 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $408.7 million versus the consensus estimate of $435.89 million.
GUIDANCE:
BioMarin Pharma sees Q4 2021 revenue of $1.82-1.88 billion, versus the consensus of $1.85 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioMarin Pharma (BMRN) Tops Q3 EPS by 11c
- SI-BONE Inc. (SIBN) Tops Q3 EPS by 5c; Offers Guidance
- Vertex Pharma (VRTX) Reports In-Line Q3 EPS; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
